MCS-2: To compare changes in I-PSS points after 12 weeks of MCS or placebo supplementation. 12 weeks [clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c]

MCS-2: To compare changes in I-PSS points after 12 weeks of MCS or placebo supplementation. 12 weeks [clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c]

Group A: MCS 30 mg/day for 12 weeks
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c
MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia [clinicaltrials:NCT00501371]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

MCS-2: To compare changes in I-PSS points after 12 weeks of MCS or placebo supplementation. 12 weeks [clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c]

Group A: MCS 30 mg/day for 12 weeks
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c
Bio2RDF identifier
cf1c2254321f2d14b36a2223912b817c
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c
measure [clinicaltrials_vocabulary:measure]
MCS-2: To compare changes in I ...... CS or placebo supplementation.
time frame [clinicaltrials_vocabulary:time-frame]
description
Group A: MCS 30 mg/day for 12 weeks
identifier
clinicaltrials_resource:cf1c2254321f2d14b36a2223912b817c
title
MCS-2: To compare changes in I ...... cebo supplementation. 12 weeks
@en
inDataset
type
label
MCS-2: To compare changes in I ...... c2254321f2d14b36a2223912b817c]
@en